Meeting
2023 ASCO Annual Meeting
Preliminary results from ERAS-007 plus palbociclib (palbo) in patients (pts) with KRAS/NRAS mutant (m) colorectal cancer (CRC) or KRASm pancreatic ductal adenocarcinoma (PDAC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers).
Authors
Susanna Varkey Ulahannan
University of Okahoma Health Sciences Center, Oklahoma City, OK
Susanna Varkey Ulahannan , David R. Spigel , Michael Sangmin Lee , Marwan Fakih , Patrick Grierson , Eric Christenson , E. Gabriela Chiorean , Darryl Alan Outlaw , Gazala Khan , Chloe Evelyn Atreya , Aparna Raj Parikh , Farshid Dayyani , Alexander I. Spira , Scott Kopetz , Andrea J. Bullock , Zhengrong Li , Xiaoying Chen , Hina Patel , Saswati Hazra , John H Strickler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT05039177
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3558)
DOI
10.1200/JCO.2023.41.16_suppl.3558
Abstract #
3558
Poster Bd #
258
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Preclinical drug testing for clinical trial planning of novel combinative therapy with PI3K and MAPK inhibitors in colorectal cancer(CRC).
First Author: Cha Len Lee
Poster
2023 ASCO Annual Meeting
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
First Author: Sara A. Hurvitz
Poster
2023 ASCO Annual Meeting
Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
First Author: Laurien Joanna Zeverijn
Poster
2023 ASCO Annual Meeting
First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program.
First Author: Elisabeth Carola